Endocrinology and Metabolism

Original Article

Thyroid
Frequency of TERT Promoter Mutations in Real-World Analysis of 2,092 Thyroid Carcinoma Patients: Heera Yang, Hyunju Park, Hyun Jin Ryu, Jung Heo, Jung-Sun Kim, Young Lyun Oh, Jun-Ho Choe, Jung Han Kim, Jee Soo Kim, Hye Won Jang, Tae Hyuk Kim, Sun Wook Kim, Jae Hoon Chung; Endocrinol Metab. 2022;37(4):652-663. Published online July 22, 2022; DOI: https://doi.org/10.3803/EnM.2022.1477

3,659 View
194 Download
11 Web of Science
13 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Telomerase reverse transcriptase (TERT) promoter mutations are associated with increased recurrence and mortality in patients with thyroid carcinoma. Previous studies on TERT promoter mutations were retrospectively conducted on a limited number of patients.
Methods
We prospectively collected data on all consecutive patients who underwent thyroid carcinoma surgery between January 2019 and December 2020 at the Samsung Medical Center, Seoul, Korea. We included 2,092 patients with thyroid carcinoma.
Results
Of 2,092 patients, 72 patients (3.4%) had TERT promoter mutations. However, the frequency of TERT promoter mutations was 0.5% in papillary thyroid microcarcinoma (PTMC) ≤1 cm and it was 5.8% in papillary thyroid carcinoma (PTC) >1 cm. The frequency of TERT promoter mutations was significantly associated with older age at diagnosis (odds ratio [OR], 1.12; P<0.001), larger primary tumor size (OR, 2.02; P<0.001), and aggressive histological type (OR, 7.78 in follicular thyroid carcinoma; OR, 10.33 in poorly differentiated thyroid carcinoma; OR, 45.92 in anaplastic thyroid carcinoma; P<0.001). Advanced T stage, advanced N stage, and distant metastasis at diagnosis were highly prevalent in mutated thyroid cancers. However, initial distant metastasis was not present in patients with TERT promoter mutations in PTMC. Although the C228T mutation was more highly detected than the C250T mutation (64 cases vs. 7 cases), there were no significant clinicopathological differences.
Conclusion
This study is the first attempt to investigate the frequency of TERT promoter mutations in a real-world setting. The frequency of TERT promoter mutations in PTC was lower than expected, and in PTMC, young patients, and female patients, the frequency was very low.

Citations

Citations to this article as recorded by

TERT Promoter Mutations Frequency Across Race, Sex, and Cancer Type
Talal El Zarif, Marc Machaalani, Rashad Nawfal, Amin H Nassar, Wanling Xie, Toni K Choueiri, Mark Pomerantz
The Oncologist.2024; 29(1): 8. CrossRef
Gene mutations as predictors of central lymph mode metastasis in cN0 PTC: A meta‐analysis
Jiaqi Ji, Xinlong Shi
Clinical Genetics.2024; 105(2): 130. CrossRef
Risk stratification by combining common genetic mutations and TERT promoter methylation in papillary thyroid cancer
Ye Sang, Guanghui Hu, Junyu Xue, Mengke Chen, Shubin Hong, Rengyun Liu
Endocrine.2024;[Epub] CrossRef
Shortened telomere length in peripheral blood leukocytes is associated with cumulative radioactive iodine doses in patients with differentiated thyroid carcinoma
Hoonsung Choi, Sun Wook Cho, Hwan Hee Kim, Ka Hee Yi, Do Joon Park, Young Joo Park
Cancer.2024;[Epub] CrossRef
2023 Update of the Korean Thyroid Association Guidelines for the Management of Thyroid Nodules
Eun Kyung Lee, Young Joo Park
Clinical Thyroidology®.2024; 36(4): 153. CrossRef
Deciphering the Functions of Telomerase Reverse Transcriptase in Head and Neck Cancer
Tsung-Jang Yeh, Chi-Wen Luo, Jeng-Shiun Du, Chien-Tzu Huang, Min-Hung Wang, Tzer-Ming Chuang, Yuh-Ching Gau, Shih-Feng Cho, Yi-Chang Liu, Hui-Hua Hsiao, Li-Tzong Chen, Mei-Ren Pan, Hui-Ching Wang, Sin-Hua Moi
Biomedicines.2023; 11(3): 691. CrossRef
2023 Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules
Young Joo Park, Eun Kyung Lee, Young Shin Song, Soo Hwan Kang, Bon Seok Koo, Sun Wook Kim, Dong Gyu Na, Seung-Kuk Baek, So Won Oh, Min Kyoung Lee, Sang-Woo Lee, Young Ah Lee, Yong Sang Lee, Ji Ye Lee, Dong-Jun Lim, Leehi Joo, Yuh-Seog Jung, Chan Kwon Jung
International Journal of Thyroidology.2023; 16(1): 1. CrossRef
Thyroid Cancer, Iodine, and Gene Mutation
Jae Hoon Chung
International Journal of Thyroidology.2023; 16(1): 89. CrossRef
Mortality rate and causes of death in papillary thyroid microcarcinoma
Jung Heo, Hyun Jin Ryu, Hyunju Park, Tae Hyuk Kim, Sun Wook Kim, Young Lyun Oh, Jae Hoon Chung
Endocrine.2023; 83(3): 671. CrossRef
TERT promoter mutations in thyroid cancer
Michiko Matsuse, Norisato Mitsutake
Endocrine Journal.2023; 70(11): 1035. CrossRef
TERT Promoter and BRAF V600E Mutations in Papillary Thyroid Cancer: A Single-Institution Experience in Korea
Min Jhi Kim, Jin Kyong Kim, Gi Jeong Kim, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Woong Youn Chung, Daham Kim, Kee-Hyun Nam
Cancers.2022; 14(19): 4928. CrossRef
Frequency of TERT Promoter Mutations in Real-World Analysis of 2,092 Thyroid Carcinoma Patients (Endocrinol Metab 2022;37:652-63, Heera Yang et al.)
Hyunju Park, Jae Hoon Chung
Endocrinology and Metabolism.2022; 37(6): 949. CrossRef
Frequency of TERT Promoter Mutations in Real-World Analysis of 2,092 Thyroid Carcinoma Patients (Endocrinol Metab 2022;37:652-63, Heera Yang et al.)
Sue Youn Kim, Chan Kwon Jung
Endocrinology and Metabolism.2022; 37(6): 947. CrossRef

Review Article

Thyroid
Mechanisms of TERT Reactivation and Its Interaction with BRAF^V600E: Young Shin Song, Young Joo Park; Endocrinol Metab. 2020;35(3):515-525. Published online September 22, 2020; DOI: https://doi.org/10.3803/EnM.2020.304

7,942 View
198 Download
9 Web of Science
10 Crossref

Abstract PDF PubReader ePub

The telomerase reverse transcriptase (TERT) gene, which is repressed in most differentiated human cells, can be reactivated by somatic TERT alterations and epigenetic modulations. Moreover, the recruitment, accessibility, and binding of transcription factors also affect the regulation of TERT expression. Reactivated TERT contributes to the development and progression of cancer through telomere lengthening-dependent and independent ways. In particular, because of recent advances in high-throughput sequencing technologies, studies on genomic alterations in various cancers that cause increased TERT transcriptional activity have been actively conducted. TERT reactivation has been reported to be associated with poor prognosis in several cancers, and TERT promoter mutations are among the most potent prognostic markers in thyroid cancer. In particular, when a TERT promoter mutation coexists with the BRAF^V600E mutation, these mutations exert synergistic effects on a poor prognosis. Efforts have been made to uncover the mechanisms of these synergistic interactions. In this review, we discuss the role of TERT reactivation in tumorigenesis, the mechanisms of TERT reactivation across all human cancers and in thyroid cancer, and the mechanisms of interactions between BRAF^V600E and TERT promoter mutations.

Citations

Citations to this article as recorded by

Adult granulosa cell tumor of the testis with malignant tendency: A case report with genetic analysis using high-throughput sequencing
Lili Deng, Jingjing Zeng, Jin Feng Qiu, Li Hua Yang, Jie Ma
Medicine.2023; 102(32): e34523. CrossRef
Genomic Analysis in the Categorization of Poorly Differentiated Primary Liver Carcinomas
Alexander T. Kikuchi, Sarah Umetsu, Nancy Joseph, Sanjay Kakar
American Journal of Surgical Pathology.2023; 47(11): 1207. CrossRef
Telomerase and hallmarks of cancer: An intricate interplay governing cancer cell evolution
Naveen kumar, Gautam Sethi
Cancer Letters.2023; 578: 216459. CrossRef
Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP): Tumour Entity with a Short History. A Review on Challenges in Our Microscopes, Molecular and Ultrasonographic Profile
Ivana Kholová, Elina Haaga, Jaroslav Ludvik, David Kalfert, Marie Ludvikova
Diagnostics.2022; 12(2): 250. CrossRef
Does Locally Advanced Thyroid Cancer Have Different Features? Results from a Single Academic Center
Marco Dell’Aquila, Pietro Tralongo, Giuseppe De Ruggieri, Mariangela Curatolo, Luca Revelli, Celestino Pio Lombardi, Alfredo Pontecorvi, Guido Fadda, Luigi Maria Larocca, Marco Raffaelli, Liron Pantanowitz, Esther Diana Rossi
Journal of Personalized Medicine.2022; 12(2): 221. CrossRef
Adult Wilms Tumor
Pedram Argani, Satish K. Tickoo, Andres Matoso, Christine A. Pratilas, Rohit Mehra, Maria Tretiakova, Mathilde Sibony, Alan K. Meeker, Ming-Tseh Lin, Victor E. Reuter, Jonathan I. Epstein, Jeffrey Gagan, Doreen N. Palsgrove
American Journal of Surgical Pathology.2022; 46(7): 988. CrossRef
Prospective Analysis of TERT Promoter Mutations in Papillary Thyroid Carcinoma at a Single Institution
Yun-Suk Choi, Seong-Woon Choi, Jin-Wook Yi
Journal of Clinical Medicine.2021; 10(10): 2179. CrossRef
How limited molecular testing can also offer diagnostic and prognostic evaluation of thyroid nodules processed with liquid‐based cytology: Role of TERT promoter and BRAF V600E mutation analysis
Marco Dell’Aquila, Vincenzo Fiorentino, Maurizio Martini, Sara Capodimonti, Tonia Cenci, Celestino Pio Lombardi, Marco Raffaelli, Alfredo Pontecorvi, Guido Fadda, Liron Pantanowitz, Luigi Maria Larocca, Esther Diana Rossi
Cancer Cytopathology.2021; 129(10): 819. CrossRef
Human telomerase reverse transcriptase and telomeres in cancer
Anurag Mehta, Shrinidhi Nathany
Journal of Current Oncology.2021; 4(1): 1. CrossRef
Mutation in Genes Encoding Key Functional Groups Additively Increase Mortality in Patients with BRAFV600E-Mutant Advanced Papillary Thyroid Carcinoma
Eyun Song, Meihua Jin, Ahreum Jang, Min Ji Jeon, Dong Eun Song, Hye Jin Yoo, Won Bae Kim, Young Kee Shong, Won Gu Kim
Cancers.2021; 13(22): 5846. CrossRef

Original Article

Clinical Study
Low Prevalence of Somatic TERT Promoter Mutations in Classic Papillary Thyroid Carcinoma: Min Ji Jeon, Won Gu Kim, Soyoung Sim, Seonhee Lim, Hyemi Kwon, Tae Yong Kim, Young Kee Shong, Won Bae Kim; Endocrinol Metab. 2016;31(1):100-104. Published online March 16, 2016; DOI: https://doi.org/10.3803/EnM.2016.31.1.100

4,352 View
32 Download
16 Web of Science
15 Crossref

Abstract PDF PubReader

Background

Transcriptional activating mutations of telomerase reverse transcriptase (TERT) are associated with more aggressive thyroid cancer. We evaluated the significance of TERT promoter mutations in Korean patients with classic papillary thyroid cancer (PTC).

Methods

Genomic DNA was isolated from four thyroid cancer cell lines and 35 fresh-frozen PTC tissues. TERT promoter mutations (C228T and C250T) and the BRAF V600E mutation were evaluated by polymerase chain reaction amplification and direct sequencing.

Results

The CC228229TT mutation in the TERT promoter was detected in BCPAP cells and the C250T mutation was found in 8505C cells. No TERT promoter mutation was observed in Cal-62 or ML-1 cells. The C228T mutation was found in only 1 of 35 (2.8%) PTCs and no C250T mutations were detected in any of the study subjects. The BRAF V600E mutation was found in 20 of 35 (57.1%) PTCs. One patient with the C228T TERT mutation also harbored the BRAF V600E mutation and developed a recurrence.

Conclusion

The prevalence of somatic TERT promoter mutations was low in Korean patients with classic PTC. Therefore, the prognostic role of TERT promoter mutations might be limited in this patient cohort.

Citations

Citations to this article as recorded by

Risk Factors for TERT Promoter Mutations with Papillary Thyroid Carcinoma Patients: A Meta-Analysis and Systematic Review
Jingxin Mao, Xingliang Huang, Mohammad K. Okla, Mostafa A. Abdel-Maksoud, Ayman Mubarak, Zahid Hameed, Razia Noreen, Aqsa Chaudhary, Shakira Ghazanfar, Yixuan Liao, Yasir Hameed, Chen Li, Min Tang
Computational and Mathematical Methods in Medicine.2022; 2022: 1. CrossRef
Telomerase reverse transcriptase promoter mutations in cancers derived from multiple organ sites among middle eastern population
Abdul K. Siraj, Rong Bu, Kaleem Iqbal, Sandeep Kumar Parvathareddy, Nabil Siraj, Sarah Siraj, Mark Ranier F. Diaz, Dionne Rae Rala, Allianah D. Benito, Maria Angelita Sabido, Maha Al-Rasheed, Khadija A.S. Al-Obaisi, Wael Al-Haqawi, Ingrid G. Victoria, Waf
Genomics.2020; 112(2): 1746. CrossRef
Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis
Jing Yang, Yanping Gong, Shuping Yan, Hui Chen, Siqin Qin, Rixiang Gong
Endocrine.2020; 67(1): 44. CrossRef
The Combination of RET, BRAF and Demographic Data Identifies Subsets of Patients with Aggressive Papillary Thyroid Cancer
Jose R. W. Martínez, Sergio Vargas-Salas, Soledad Urra Gamboa, Estefanía Muñoz, José Miguel Domínguez, Augusto León, Nicolás Droppelmann, Antonieta Solar, Mark Zafereo, F. Christopher Holsinger, Hernán E. González
Hormones and Cancer.2019; 10(2-3): 97. CrossRef
Correlation between TERT C228T and clinic-pathological features in pediatric papillary thyroid carcinoma
Jiangqiao Geng, Yuanhu Liu, Yongli Guo, Huanmin Wang, Jun Tai, Yaqiong Jin, Jie Zhang, Yongbo Yu, Shengcai Wang, Yingluan Song, Xin Ni
Science China Life Sciences.2019; 62(12): 1563. CrossRef
Human telomerase reverse transcriptase in papillary thyroid cancer: gene expression, effects of silencing and regulation by BET inhibitors in thyroid cancer cells
Valentina Maggisano, Marilena Celano, Saverio Massimo Lepore, Marialuisa Sponziello, Francesca Rosignolo, Valeria Pecce, Antonella Verrienti, Federica Baldan, Catia Mio, Lorenzo Allegri, Marianna Maranghi, Rosa Falcone, Giuseppe Damante, Diego Russo, Stef
Endocrine.2019; 63(3): 545. CrossRef
BRAF and RAS Mutational Status in Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features and Invasive Subtype of Encapsulated Follicular Variant of Papillary Thyroid Carcinoma in Korea
Mijin Kim, Min Ji Jeon, Hye-Seon Oh, Suyeon Park, Tae Yong Kim, Young Kee Shong, Won Bae Kim, Kyunggon Kim, Won Gu Kim, Dong Eun Song
Thyroid.2018; 28(4): 504. CrossRef
The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer
Anqi Jin, Jianhao Xu, Yan Wang
Medicine.2018; 97(29): e11548. CrossRef
Telomere Maintenance Mechanisms in Cancer
Tiago Bordeira Gaspar, Ana Sá, José Manuel Lopes, Manuel Sobrinho-Simões, Paula Soares, João Vinagre
Genes.2018; 9(5): 241. CrossRef
Anti-hTERT siRNA-Loaded Nanoparticles Block the Growth of Anaplastic Thyroid Cancer Xenograft
Giovanni E. Lombardo, Valentina Maggisano, Marilena Celano, Donato Cosco, Chiara Mignogna, Federica Baldan, Saverio M. Lepore, Lorenzo Allegri, Sonia Moretti, Cosimo Durante, Giuseppe Damante, Massimo Fresta, Diego Russo, Stefania Bulotta, Efisio Puxeddu
Molecular Cancer Therapeutics.2018; 17(6): 1187. CrossRef
Silencing of hTERT blocks growth and migration of anaplastic thyroid cancer cells
Valentina Maggisano, Marilena Celano, Giovanni Enrico Lombardo, Saverio Massimo Lepore, Marialuisa Sponziello, Francesca Rosignolo, Antonella Verrienti, Federica Baldan, Efisio Puxeddu, Cosimo Durante, Sebastiano Filetti, Giuseppe Damante, Diego Russo, St
Molecular and Cellular Endocrinology.2017; 448: 34. CrossRef
Articles inEndocrinology and Metabolismin 2016
Won-Young Lee
Endocrinology and Metabolism.2017; 32(1): 62. CrossRef
Telomerase: The Devil Inside
Mukesh Kumar, Andre Lechel, Çagatay Güneş
Genes.2016; 7(8): 43. CrossRef
Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications
Tiantian Liu, Xiaotian Yuan, Dawei Xu
Genes.2016; 7(7): 38. CrossRef
Transcription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) Gene
Muhammad Ramlee, Jing Wang, Wei Toh, Shang Li
Genes.2016; 7(8): 50. CrossRef

Review Article

Thyroid
Mutation Profile of Well-Differentiated Thyroid Cancer in Asians: Young Shin Song, Jung Ah Lim, Young Joo Park; Endocrinol Metab. 2015;30(3):252-262. Published online September 22, 2015; DOI: https://doi.org/10.3803/EnM.2015.30.3.252

5,187 View
64 Download
60 Web of Science
52 Crossref

Abstract PDF PubReader

Recent advances in molecular diagnostics have led to significant insights into the genetic basis of thyroid tumorigenesis. Among the mutations commonly seen in thyroid cancers, the vast majority are associated with the mitogen-activated protein kinase pathway. B-Raf proto-oncogene (BRAF) mutations are the most common mutations observed in papillary thyroid cancers (PTCs), followed by RET/PTC rearrangements and RAS mutations, while follicular thyroid cancers are more likely to harbor RAS mutations or PAX8/peroxisome proliferator-activated receptor γ (PPARγ) rearrangements. Beyond these more common mutations, alterations in the telomerase reverse transcriptase (TERT) promoter have recently been associated with clinicopathologic features, disease prognosis, and tumorigenesis in thyroid cancer. While the mutations underlying thyroid tumorigenesis are well known, the frequency of these mutations is strongly associated with geography, with clear differences reported between Asian and Western countries. Of particular interest is the prevalence of BRAF mutations, with Korean patients exhibiting the highest rate of BRAF-associated thyroid cancers in the world. Here, we review the prevalence of each of the most common mutations in Asian and Western countries, and identify the characteristics of well-differentiated thyroid cancer in Asians.

Citations

Citations to this article as recorded by

BRAF V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma
Hon-Fan Lai, Jen-Fan Hang, Po-Chung Kuo, Chin-Sung Kuo, San-Fan Yao, Jui-Yu Chen, Chen-Hsen Lee
Annals of Surgical Oncology.2024; 31(5): 3495. CrossRef
Clinical value of multi-gene testing in distinguishing benign and malignant thyroid nodules
Murui Zhang, Xiaotong Hu, Lunming Liu, Yihong Wang, Junchang Jiang, Hui Li, Weiqiang Fei, Tingting Zhong, Zhinong Jiang
Medicine.2024; 103(4): e35960. CrossRef
The Association of Socioeconomic Factors and Well-Differentiated Thyroid Cancer
Andrew Bonner, Brendon Herring, Rongzhi Wang, Andrea Gillis, Polina Zmijewski, Brenessa Lindeman, Jessica Fazendin, Herbert Chen
Journal of Surgical Research.2023; 283: 973. CrossRef
BRAFV600E and TERT promoter C228T mutations on ThyroSeq v3 analysis of delayed skin metastasis from papillary thyroid cancer: a case report and literature review
Jee-Hye Choi, Hyeong Won Yu, Ja Kyung Lee, Woochul Kim, June Young Choi, Hee Young Na, So Yeon Park, Chang Ho Ahn, Jae Hoon Moon, Sang Il Choi, Ho-Young Lee, Won Woo Lee, Wonjae Cha, Woo-Jin Jeong
World Journal of Surgical Oncology.2023;[Epub] CrossRef
Less is more meets do more with less: Exploring differences in thyroid FNA molecular testing between Asian and Western practices
Michiya Nishino
Cancer Cytopathology.2023; 131(7): 421. CrossRef
Histological and Genetic Diversity in Ovarian Mucinous Carcinomas: A Pilot Study
Sultana Razia, Kentaro Nakayama, Hitomi Yamashita, Tomoka Ishibashi, Masako Ishikawa, Kosuke Kanno, Seiya Sato, Satoru Kyo
Current Oncology.2023; 30(4): 4052. CrossRef
Effective Use of microRNA, BRAF and Sonographic Risk Assessment in Bethesda III Thyroid Nodules Requires a Different Approach to Nodules with Features of Nuclear Atypia and Other Types of Atypia
Dorota Słowińska-Klencka, Bożena Popowicz, Dominika Kulczycka-Wojdala, Bożena Szymańska, Joanna Duda-Szymańska, Martyna Wojtaszek-Nowicka, Krzysztof Kaczka, Mariusz Klencki
Cancers.2023; 15(17): 4287. CrossRef
Long-Term Changes in the Mortality Rates of Thyroid Cancer in Korea: Analysis of Korean National Data from 1985 to 2020
Yun Mi Choi, Min-Ju Kim, Jiwoo Lee, Mi Kyung Kwak, Min Ji Jeon, Tae Yong Kim, Eun-Gyoung Hong, Won Bae Kim, Won Gu Kim
Endocrinology and Metabolism.2023; 38(5): 588. CrossRef
遺伝子から頭頸部がんを診る : 甲状腺癌 (分化癌を中心に)
季吉森谷
Nippon Jibiinkoka Tokeibugeka Gakkai Kaiho(Tokyo).2023; 126(12): 1277. CrossRef
Toward Systems-Level Metabolic Analysis in Endocrine Disorders and Cancer
Aliya Lakhani, Da Hyun Kang, Yea Eun Kang, Junyoung O. Park
Endocrinology and Metabolism.2023; 38(6): 619. CrossRef
Risk and Prognostic Factors for BRAFV600E Mutations in Papillary Thyroid Carcinoma
Xiaojing Wei, Xiaodong Wang, Jie Xiong, Chen Li, Yixuan Liao, Yongjun Zhu, Jingxin Mao, Gitana Maria Aceto
BioMed Research International.2022; 2022: 1. CrossRef
Disparities in the impact of the AJCC 8th edition staging system on differentiated thyroid cancer outcomes
Juan A. Santamaria‐Barria, Amanda N. Graff‐Baker, Shu‐Ching Chang, Adam Khader, Anthony J. Scholer, Mary Garland‐Kledzik, Melanie Goldfarb
Head & Neck.2022; 44(10): 2129. CrossRef
Relationship Between The BRAF V600E And Tumor Size, Lymph Node, And Distant Metastasis In Papillary Thyroid Carcinoma
Edmond Rukmana Wikanta, Yan Wisnu Prajoko, Benny Issakh, Hermawan Istiadi, Dik Puspasari
Russian Open Medical Journal.2022;[Epub] CrossRef
Lactate Dehydrogenase A as a Potential New Biomarker for Thyroid Cancer
Eun Jeong Ban, Daham Kim, Jin Kyong Kim, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Kunhong Kim
Endocrinology and Metabolism.2021; 36(1): 96. CrossRef
Association of Hyperparathyroidism and Papillary Thyroid Cancer: A Multicenter Retrospective Study (Endocrinol Metab 2020;35:925-32, Chaiho Jeong et al.)
Chaiho Jeong, Jeonghoon Ha, Moo Il Kang
Endocrinology and Metabolism.2021; 36(1): 205. CrossRef
Molecular pathogenesis of pediatric thyroid carcinoma
Norisato Mitsutake, Vladimir Saenko
Journal of Radiation Research.2021; 62(Supplement): i71. CrossRef
The Incidence of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: A Meta-Analysis Assessing Worldwide Impact of the Reclassification
Chanchal Rana, Huy Gia Vuong, Thu Quynh Nguyen, Hoang Cong Nguyen, Chan Kwon Jung, Kennichi Kakudo, Andrey Bychkov
Thyroid.2021;[Epub] CrossRef
The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and BRAFV600E Mutation
Tauangtham Anekpuritanang, Maythad Uataya, Apichaya Claimon, Natthawadee Laokulrath, Warut Pongsapich, Paveena Pithuksurachai
OncoTargets and Therapy.2021; Volume 14: 3959. CrossRef
Genomic landscape of metastatic papillary thyroid carcinoma and novel biomarkers for predicting distant metastasis
Xiabin Lan, Hua Bao, Xinyang Ge, Jun Cao, Xiaojun Fan, Qihong Zhang, Kaihua Liu, Xian Zhang, Zhuo Tan, Chuanming Zheng, Ao Wang, Chao Chen, Xin Zhu, Jiafeng Wang, Jiajie Xu, Xuhang Zhu, Xue Wu, Xiaonan Wang, Yang Shao, Minghua Ge
Cancer Science.2020; 111(6): 2163. CrossRef
Did Introducing a New Category of Thyroid Tumors (Non-invasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features) Decrease the Risk of Malignancy for the Diagnostic Categories in the Bethesda System for Reporting Thyroid Cytopathology?
Janusz Kopczyński, Agnieszka Suligowska, Kornelia Niemyska, Iwona Pałyga, Agnieszka Walczyk, Danuta Gąsior-Perczak, Artur Kowalik, Kinga Hińcza, Ryszard Mężyk, Stanisław Góźdź, Aldona Kowalska
Endocrine Pathology.2020; 31(2): 143. CrossRef
The Significance of Transcriptomic Signatures in the Multifocal Papillary Thyroid Carcinoma: Two mRNA Expression Patterns with Distinctive Clinical Behavior from The Cancer Genome Atlas (TCGA) Database
Yea Eun Kang, Boyoung Hwang, Ju Hee Lee, Minho Shong, Hyon-Seung Yi, Bon Seok Koo, Dong Jin Lee
International Journal of Thyroidology.2020; 13(1): 1. CrossRef
High Genetic Diversity and No Evidence of Clonal Relation in Synchronous Thyroid Carcinomas Associated with Hashimoto’s Thyroiditis: A Next-Generation Sequencing Analysis
Csaba Molnár, Emese Sarolta Bádon, Attila Mokánszki, Anikó Mónus, Lívia Beke, Ferenc Győry, Endre Nagy, Gábor Méhes
Diagnostics.2020; 10(1): 48. CrossRef
Low Prevalence of TERT Promoter, BRAF and RAS Mutations in Papillary Thyroid Cancer in the Greek Population
Marilena Argyropoulou, Aristidis S. Veskoukis, Pagona-Maria Karanatsiou, Aikaterini Manolakelli, Ifigenia Kostoglou-Athanassiou, George Vilaras, Andreas Karameris, Kalliopi Liadaki
Pathology & Oncology Research.2020; 26(1): 347. CrossRef
Predominant DICER1 Pathogenic Variants in Pediatric Follicular Thyroid Carcinomas
Young Ah Lee, Sun-Wha Im, Kyeong Cheon Jung, Eun-Jae Chung, Choong Ho Shin, Jong-Il Kim, Young Joo Park
Thyroid.2020; 30(8): 1120. CrossRef
BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates
Suhail Al-Salam, Charu Sharma, Bachar Afandi, Khaled Al Dahmani, Ali S. Al-Zahrani, Amal Al Shamsi, Juma Al Kaabi, Paula Soares
PLOS ONE.2020; 15(4): e0231341. CrossRef
VE1 Immunohistochemistry Improves the Limit of Genotyping for Detecting BRAFV600E Mutation in Papillary Thyroid Cancer
Sonam Choden, Somboon Keelawat, Chan Kwon Jung, Andrey Bychkov
Cancers.2020; 12(3): 596. CrossRef
Highly Sensitive and Specific Molecular Test for Mutations in the Diagnosis of Thyroid Nodules: A Prospective Study of BRAF-Prevalent Population
Yoon Young Cho, So Young Park, Jung Hee Shin, Young Lyun Oh, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim, Hyun Sook Yim, Yoo-Li Kim, Chang-Seok Ki, Tae Hyuk Kim, Jae Hoon Chung, Sun Wook Kim
International Journal of Molecular Sciences.2020; 21(16): 5629. CrossRef
Is there adenoma-carcinoma sequence between benign adenoma and papillary cancer of thyroid: A genomic linkage study
Ramesh Bangaraiahgari, Ramakanth Bhargav Panchangam, Pradeep Puthenveetil, Sabaretnam Mayilvaganan, Rajesh Bangaraiahgari, Rajkiran reddy Banala, Poongkodi Karunakaran, Rafi Md
Annals of Medicine and Surgery.2020; 60: 695. CrossRef
Genomic Characterization of Differentiated Thyroid Carcinoma
Young Shin Song, Young Joo Park
Endocrinology and Metabolism.2019; 34(1): 1. CrossRef
Association between BRAFV600E Mutations and Clinicopathological Features of Papillary Thyroid Microcarcinoma (PTMC)
Sung Min Lee, Cho Rok Lee, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Cheong Soo Park
Journal of Endocrine Surgery.2019; 19(3): 76. CrossRef
Combined quantitation of HMGA2 mRNA, microRNAs, and mitochondrial-DNA content enables the identification and typing of thyroid tumors in fine-needle aspiration smears
Sergei E. Titov, Mikhail K. Ivanov, Pavel S. Demenkov, Gevork A. Katanyan, Eugenia S. Kozorezova, Anastasia V. Malek, Yulia A. Veryaskina, Igor F. Zhimulev
BMC Cancer.2019;[Epub] CrossRef
Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer
Young Shin Song, Seong-Keun Yoo, Hwan Hee Kim, Gyeongseo Jung, Ah-Reum Oh, Ji-Young Cha, Su-jin Kim, Sun Wook Cho, Kyu Eun Lee, Jeong-Sun Seo, Young Joo Park
Endocrine-Related Cancer.2019; 26(6): 629. CrossRef
Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features in Asian Practice: Perspectives for Surgical Pathology and Cytopathology
Andrey Bychkov, Chan Kwon Jung, Zhiyan Liu, Kennichi Kakudo
Endocrine Pathology.2018; 29(3): 276. CrossRef
Understanding Malignancies of the Thyroid Gland: Institutional Experience
Jaimanti Bakshi, Sourabha Kumar Patro, Navjot Kaur, Naresh Kumar Panda, Grace Budhiraja
Indian Journal of Otolaryngology and Head & Neck Surgery.2018; 70(4): 482. CrossRef
Case–Control Study of Papillary Thyroid Carcinoma on Urinary and Dietary Iodine Status in South Korea
Joon‐Hyop Lee, Ra‐Yeong Song, Jin Wook Yi, Hyeong Won Yu, Hyungju Kwon, Su‐jin Kim, Young Jun Chai, June Young Choi, Jae Hoon Moon, Kyu Eun Lee, Young Joo Park, Sue K. Park
World Journal of Surgery.2018; 42(5): 1424. CrossRef
Impact of non-invasive follicular thyroid neoplasm with papillary-like nuclear features on the Bethesda system for reporting thyroid cytopathology: a multi-institutional study in five Asian countries
Andrey Bychkov, Somboon Keelawat, Shipra Agarwal, Deepali Jain, Chan Kwon Jung, SoonWon Hong, Chiung-Ru Lai, Shinya Satoh, Kennichi Kakudo
Pathology.2018; 50(4): 411. CrossRef
Genetic landscape of papillary thyroid carcinoma in the Chinese population
Jialong Liang, Wanshi Cai, Dongdong Feng, Huajing Teng, Fengbiao Mao, Yi Jiang, Shanshan Hu, Xianfeng Li, Yujie Zhang, Baoguo Liu, Zhong Sheng Sun
The Journal of Pathology.2018; 244(2): 215. CrossRef
Aberrant expression of CD20 in thyroid cancer and its clinicopathologic significance
Andrey Bychkov, Chan Kwon Jung
Human Pathology.2018; 71: 74. CrossRef
Molecular markers in well-differentiated thyroid cancer
Anil K. D’Cruz, Richa Vaish, Abhishek Vaidya, Iain J. Nixon, Michelle D. Williams, Vincent Vander Poorten, Fernando López, Peter Angelos, Ashok R. Shaha, Avi Khafif, Alena Skalova, Alessandra Rinaldo, Jennifer L. Hunt, Alfio Ferlito
European Archives of Oto-Rhino-Laryngology.2018; 275(6): 1375. CrossRef
Meta-Analysis Confirms the Deleterious Effects of CombinedBRAFV600Eand Telomerase Reverse Transcriptase Promoter Mutations on the Course and Mortality of Papillary Thyroid Carcinoma
Charles H. Emerson
Clinical Thyroidology.2017; 29(5): 176. CrossRef
Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer
Min-Young Lee, Bo Mi Ku, Hae Su Kim, Ji Yun Lee, Sung Hee Lim, Jong-Mu Sun, Se-Hoon Lee, Keunchil Park, Young Lyun Oh, Mineui Hong, Han-Sin Jeong, Young-Ik Son, Chung-Hwan Baek, Myung-Ju Ahn
Cancer Research and Treatment.2017; 49(4): 906. CrossRef
Frequent BRAF V600E and Absence of TERT Promoter Mutations Characterize Sporadic Pediatric Papillary Thyroid Carcinomas in Japan
Naoki Oishi, Tetsuo Kondo, Tadao Nakazawa, Kunio Mochizuki, Tomohiro Inoue, Kazunari Kasai, Ippei Tahara, Tomonori Yabuta, Mitsuyoshi Hirokawa, Akira Miyauchi, Ryohei Katoh
Endocrine Pathology.2017; 28(2): 103. CrossRef
Predicting Factors for Bilaterality in Papillary Thyroid Carcinoma with Tumor Size <4 cm
Seo Ki Kim, Inhye Park, Jung-Woo Woo, Jun Ho Lee, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim
Thyroid.2017; 27(2): 207. CrossRef
Low Rate of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features in Asian Practice
Andrey Bychkov, Mitsuyoshi Hirokawa, Chan Kwon Jung, Zhiyan Liu, Yun Zhu, Soon Won Hong, Shinya Satoh, Chiung-Ru Lai, Lien Huynh, Kennichi Kakudo
Thyroid.2017; 27(7): 983. CrossRef
Changes in the clinicopathological characteristics and genetic alterations of follicular thyroid cancer
Young Shin Song, Jung Ah Lim, Hye Sook Min, Min Joo Kim, Hoon Sung Choi, Sun Wook Cho, Jae Hoon Moon, Ka Hee Yi, Do Joon Park, Bo Youn Cho, Young Joo Park
European Journal of Endocrinology.2017; 177(6): 465. CrossRef
Effects of CoexistentBRAFV600EandTERTPromoter Mutations on Poor Clinical Outcomes in Papillary Thyroid Cancer: A Meta-Analysis
Shinje Moon, Young Shin Song, Ye An Kim, Jung Ah Lim, Sun Wook Cho, Jae Hoon Moon, Seokyung Hahn, Do Joon Park, Young Joo Park
Thyroid.2017; 27(5): 651. CrossRef
TERT Promoter Mutation in an Aggressive Cribriform Morular Variant of Papillary Thyroid Carcinoma
Eun Ji Oh, Sohee Lee, Ja Seong Bae, Yourha Kim, Sora Jeon, Chan Kwon Jung
Endocrine Pathology.2017; 28(1): 49. CrossRef
TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer
Xue Yang, Jiao Li, Xiaoyi Li, Zhiyong Liang, Wen Gao, Jun Liang, Shujun Cheng, Yansong Lin
Journal of Nuclear Medicine.2017; 58(2): 258. CrossRef
Molecular Diagnosis Using Residual Liquid-Based Cytology Materials for Patients with Nondiagnostic or Indeterminate Thyroid Nodules
Hyemi Kwon, Won Gu Kim, Markus Eszlinger, Ralf Paschke, Dong Eun Song, Mijin Kim, Suyeon Park, Min Ji Jeon, Tae Yong Kim, Young Kee Shong, Won Bae Kim
Endocrinology and Metabolism.2016; 31(4): 586. CrossRef
TERT promoter mutations and long-term survival in patients with thyroid cancer
Tae Hyuk Kim, Young-Eun Kim, Soomin Ahn, Ji-Youn Kim, Chang-Seok Ki, Young Lyun Oh, Kyunga Kim, Jae Won Yun, Woong-Yang Park, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim, Sun Wook Kim, Jae Hoon Chung
Endocrine-Related Cancer.2016; 23(10): 813. CrossRef
Reply:
Y. Che
American Journal of Neuroradiology.2016; 37(1): E9. CrossRef
Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients
Young Shin Song, Jung Ah Lim, Hoonsung Choi, Jae‐Kyung Won, Jae Hoon Moon, Sun Wook Cho, Kyu Eun Lee, Young Joo Park, Ka Hee Yi, Do Joon Park, Jeong‐Sun Seo
Cancer.2016; 122(9): 1370. CrossRef

First
Prev
Page of 1
Next
Last

Search